Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer [ID6381]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC